Glucarpidase

Drug Profile

Glucarpidase

Alternative Names: Carboxypeptidase G2; CPG2; OP 07; OP-07 - Ohara Pharmaceuticals; Voraxaze

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Health Protection Agency Porton Down
  • Developer BTG; Ohara Pharmaceutical
  • Class Carboxypeptidases
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage; Chemoprotection
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemoprotection; Chemotherapy-induced damage

Most Recent Events

  • 09 Jan 2017 Phase-II clinical trials in Chemoprotection in Japan (IV) before January 2017 (Ohara Pharmaceuticals pipeline, January 2017)
  • 09 Jan 2017 Phase-II clinical trials in Chemotherapy induced damage in Japan (IV) (Ohara Pharmaceuticals pipeline, January 2017)
  • 04 Jun 2012 Efficacy and adverse events data from a clinical trial in Chemotherapy induced damage/Chemoprotection released by BTG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top